跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

D9446

Sigma-Aldrich

L-DOPS

≥98% (HPLC)

别名:

L-苏-3,4-二羟基苯基丝氨酸, 屈西多巴

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C9H11NO5
CAS号:
23651-95-8
分子量:
213.19
MDL编号:
MFCD00799030
UNSPSC代码:
12352200
PubChem化学物质编号:
329798902
NACRES:
NA.77

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to tan

溶解性

DMSO: ≥3 mg/mL

储存温度

−20°C

SMILES字符串

N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1

InChI key

QXWYKJLNLSIPIN-JGVFFNPUSA-N

基因信息

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146) , ADRA2A(150) , ADRA2B(151) , ADRA2C(152) , ADRB1(153) , ADRB2(154) , ADRB3(155)

一般描述

L-DOPS又名L-苏-3,4-二羟基苯基丝氨酸或屈昔多巴，是一种儿茶酚胺。L-DOPS具有多种临床优势并可用于治疗去甲肾上腺素缺乏症。它可用于治疗神经源性直立性低血压并改善去甲肾上腺素水平。L-DOPS介导淀粉样斑块的减少，并具有治疗淀粉样蛋白病理学的潜力。

应用

L-DOPS已用于具有淀粉样蛋白病理学小鼠的临床试验研究。

生化/生理作用

L-DOPS是体内去甲肾上腺素的一种前体。

特点和优势

该化合物收录于《受体分类和信号转导》手册的多巴胺、去甲肾上腺素和肾上腺素代谢页面。想要浏览手册的其他页面， 请单击此处。

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H315,H319,H335

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000422237
0000422235
0000422237
0000422235
0000414816

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Hui-Jeong Gwon et al.
Biotechnology letters, 32(1), 143-149 (2009-09-18)
Diastereoselectivity-enhanced mutants of L: -threonine aldolase (L: -TA) for L: -threo-3,4-dihydroxyphenylserine (L: -threo-DOPS) synthesis were isolated by error-prone PCR followed by a high-throughput screening. The most improved mutant was achieved from the mutant T3-3mm2, showing a 4-fold increase over the
David S Goldstein
Cardiovascular drug reviews, 24(3-4), 189-203 (2007-01-12)
L-threo-3,4-dihydroxyphenylserine (L-DOPS, droxydopa) is a synthetic catecholamino acid. When taken orally, L-DOPS is converted to the sympathetic neurotransmitter, norepinephrine (NE), via decarboxylation catalyzed by L-aromatic-amino-acid decarboxylase (LAAAD). Plasma L-DOPS levels peak at about 3 h, followed by a monoexponential decline
L-DOPS and the treatment of neurogenic orthostatic hypotension
Vichayanrat E, et al.
Future Neurology, 8(4), 381-397 (2013)
Reyhaneh Torkzadeh-Mahani et al.
Ultrasonics sonochemistry, 56, 183-192 (2019-05-19)
The present work deals with the preparation of NiO/Co3O4 nanocomposites in presence of ultrasonic irradiation, and its use in electrochemical determination of Parkinson's drugs. NiO/Co3O4 nanocomposites are prepared using ultrasound assisted method. The impact of ultrasonic irradiation power (0, 75
Robbert W K Borgemeester et al.
Parkinsonism & related disorders, 23, 17-22 (2015-12-29)
Continuous apomorphine infusion (CAI) is an effective treatment in fluctuating Parkinson's disease (PD). However, long-term efficacy and safety data of CAI are scarce. We retrospectively reviewed long-term outcomes of CAI on motor and non-motor symptoms in a Dutch cohort of
查看所有相关文献

商品

Dopamine, Norepinephrine and Ephinephrine Synthesis

Dopamine-β-hydroxylase is located inside amine storage vesicles of norepinephrine neurons. Dopamine is actively transported from the cytoplasm into the vesicles. As the enzyme is a copper containing protein, its activity can be inhibited by copper chelating agents, such as diethyldithiocarbamate and FLA-63. Inhibition of the enzyme effectively reduces tissue norepinephrine levels.

多巴胺、去甲肾上腺素和肾上腺素的合成

多巴胺-β-羟化酶位于去甲肾上腺素神经元的胺存储囊泡内。多巴胺通过主动运输而从细胞质转运到囊泡中。由于该酶是一种含铜的蛋白质，因此其活性会被铜螯合剂，如二乙基二硫代氨基甲酸酯和FLA-63所抑制。对该酶的抑制可有效降低组织去甲肾上腺素的水平。

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持